Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02194985 · ClinicalTrials.gov registry record · Phase 3
Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease
A Phase 3 study, sponsored by Amicus Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 84
- Enrollment target
NCT02194985 is a Phase 3 study that has completed, run by Amicus Therapeutics. The registered enrollment target is 84 participants.
The verdict
NCT02194985, a Phase 3 study, has completed, sponsored by Amicus Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 84 participants
- Enrollment target
Study Summary
This is an open-label extension study intended to provide continued treatment with migalastat hydrochloride (HCl) for participants with Fabry disease who completed treatment of a previous migalastat HCl study. The study assessed the long-term safety and effectiveness of migalastat HCl.
Interventions
- DRUG migalastat HCl 150 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2015-03-14 |
| Est. Completion | 2019-10-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02194985
The ClinicalTrials.gov registry entry for NCT02194985 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amicus Therapeutics, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which migalastat HCl 150 mg is the first listed.
NCT02194985 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02194985 about?
NCT02194985 is a clinical study titled "Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease". This is an open-label extension study intended to provide continued treatment with migalastat hydrochloride (HCl) for participants with Fabry disease who completed treatment of a previous migalastat HCl study. The study assessed the long-term safety and effectiveness of migalastat HCl.
What is the current status of trial NCT02194985?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 84 participants. The study started on 2015-03-14. Estimated completion is 2019-10-23.
What interventions are being tested in trial NCT02194985?
The interventions under investigation include: migalastat HCl 150 mg (DRUG).
Who is sponsoring clinical trial NCT02194985?
This trial is sponsored by Amicus Therapeutics, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.